Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Eric Andrew Collisson"'
Autor:
Viswesh Krishna, Ekin Tiu, Vrishab Krishna, Damir Vrabac, Kunal Shah, Waleed Abuzeid, Katelyn Smith, John Davelaar, Christopher Nuesca, Brent K Larson, Christos Fountzilas, Pranav Rajpurkar, Andrew Eugene Hendifar, Eric Andrew Collisson, Anirudh Joshi, Aatur D. Singhi
Publikováno v:
Journal of Clinical Oncology. 41:743-743
743 Background: The prognosis of metastatic pancreatic ductal adenocarcinoma (mPDAC) remains poor with a median survival time of 10-12 months. First-line treatment is largely influenced by performance status with fit patients more often receiving FOL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::965dbb36f1f39eb326ed643a6052978e
https://doi.org/10.1200/jco.2023.41.4_suppl.743
https://doi.org/10.1200/jco.2023.41.4_suppl.743
Autor:
Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric Andrew Collisson, Michael Jordan Fisch, Dvir Aran
Publikováno v:
Journal of Clinical Oncology. 40:e16271-e16271
e16271 Background: The common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC) are FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem-Nab-P). However, these treatments have not been directly compared in a clinical trial and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04e510cd715cf9a79cd137f37e109f80
https://doi.org/10.1200/jco.2022.40.16_suppl.e16271
https://doi.org/10.1200/jco.2022.40.16_suppl.e16271
Autor:
Viswesh Krishna, Vivek Nimgaonkar, Ekin Tiu, Vrishab Krishna, Hriday Bhambhvani, Stephen Cook, Daniel Miller, Damir Vrabac, Anirudh Joshi, Aatur D. Singhi, Andrew Eugene Hendifar, Pranav Rajpurkar, Eric Andrew Collisson
Publikováno v:
Journal of Clinical Oncology. 40:e16295-e16295
e16295 Background: Adjuvant chemotherapy improves survival following resection of pancreatic ductal adenocarcinoma (PDAC). A modified fluorouracil/irinotecan/oxaliplatin regimen (mFOLFIRINOX) has demonstrated improved disease free survival and overal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6dec1d5296a9003a6ecb22d2044da7c
https://doi.org/10.1200/jco.2022.40.16_suppl.e16295
https://doi.org/10.1200/jco.2022.40.16_suppl.e16295
Autor:
Andrea Grace Bocobo, Renee Wang, Spencer Behr, Julia C. Carnevale, Pelin Cinar, Eric Andrew Collisson, Lawrence Fong, Bridget P Keenan, Wesley Allen Kidder, Andrew H. Ko, Kanti Pallav Kolli, Megan Kennedy, Angela Laffan, Sorbarikor Piawah, Marin Pollak, Gabriel Schwartz, Julia Whitman, Li Zhang, Katherine Van Loon, Chloe Evelyn Atreya
Publikováno v:
Journal of Clinical Oncology. 40:3565-3565
3565 Background: MSS mCRC rarely responds to pembrolizumab monotherapy, but capecitabine and bevacizumab may induce immune-stimulatory effects. This study evaluates the safety, tolerability and preliminary efficacy of pembrolizumab in combination wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b0cb7553bec6240e5c442e36d6a2bbe
https://doi.org/10.1200/jco.2022.40.16_suppl.3565
https://doi.org/10.1200/jco.2022.40.16_suppl.3565
Autor:
Vincent J. Picozzi, Anne-Marie Duliege, Eric Andrew Collisson, Anirban Maitra, Manuel Hidalgo, Andrew Eugene Hendifar, Gregory Lawrence Beatty, Sudheer Doss, Lynn McCormick Matrisian, Pamela S Herena, Julie Fleshman, Michelle A. Detry, Donald A. Berry, Diane M. Simeone
Publikováno v:
Journal of Clinical Oncology. 40:TPS4188-TPS4188
TPS4188 Background: The success rate of drug development in PDAC is disappointingly low.PrP is a transformative, adaptive platform clinical trial designed to continuously evaluate many novel therapeutic options while increasing the probability that p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7510c05945ddc38689cb166ef06acc4
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4188
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4188
Optimizing pancreatic cancer management with next generation imaging and liquid biopsy (CHANGE-PDAC)
Autor:
Erica S Tsang, Eric Andrew Collisson, Zhen J. Wang, Sorbarikor Piawah, Taylor Sanchez, Margaret A. Tempero, Andrew H. Ko
Publikováno v:
Journal of Clinical Oncology. 40:TPS640-TPS640
TPS640 Background: Pancreatic ductal adenocarcinoma (PDAC) is anticipated to become the second-leading cause of cancer-related deaths by 2030. Systemic therapy remains the mainstay of treatment for those with unresectable/metastatic disease. There is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7805c269f3519a73e08aa2f59afc024c
https://doi.org/10.1200/jco.2022.40.4_suppl.tps640
https://doi.org/10.1200/jco.2022.40.4_suppl.tps640
Autor:
Amy Patricia Moore, Thach-Giao Truong, Kenneth Ted Thurn, Scott Thomas, Charles J. Ryan, Thierry Marie Jahan, Steven G. DuBois, John K. Chan, Hope S. Rugo, Eric Andrew Collisson, Paromita Raha, Stephanie Chen, Anne Reinert, Adil Daud, Pamela N. Munster
Publikováno v:
Journal of Clinical Oncology. 30:3058-3058
3058 Background: Preclinical and clinical data suggest pre-exposure of cancer cells to a histone deacetylase inhibitor (HDACi) potentiates topoisomerase inhibitors. HDACi-induced histone acetylation and chromatin modulation facilitates DNA access and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3faba629ecca0cfa87a97398bf35cae0
https://doi.org/10.1200/jco.2012.30.15_suppl.3058
https://doi.org/10.1200/jco.2012.30.15_suppl.3058